On Aug. 13, 2024, Eli Lilly announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly’s efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration and chronic pain.

LSC occupies 346,000 square feet in a 12-story building, developed and operated by Alexandria Real Estate Equities (ARE), in the rapidly expanding Seaport district of Boston. LSC accommodates approximately 500 Lilly scientists and researchers, in addition to 200 people from the companies within Lilly Gateway Labs.